About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Section of Oncology
›
top-articles
Section of Oncology
146
(top 1%)
papers
13.2K
(top 1%)
citations
40
(top 1%)
h
-index
115
(top 1%)
g
-index
158
all documents
14.5K
doc citations
2.0K
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
Signatures of mutational processes in human cancer
Nature
2013
8,060
2
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
Nature Genetics
2009
862
3
Subclonal diversification of primary breast cancer revealed by multiregion sequencing
Nature Medicine
2015
711
4
Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
Clinical Cancer Research
2009
297
5
Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer
Nature Genetics
2014
254
6
Somatic mutations reveal asymmetric cellular dynamics in the early human embryo
Nature
2017
229
7
Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer
Radiotherapy and Oncology
2003
170
8
Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis
British Journal of Cancer
2009
123
9
The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians
Cancer Cell
2011
104
10
Impaired health-related quality of life after chemoradiotherapy for anal cancer: Late effects in a national cohort of 128 survivors
Acta Oncológica
2013
102
11
Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter?
Oncologist
2008
101
12
Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group
Acta Oncológica
2005
94
13
Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study
European Journal of Cancer
2006
92
14
Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status
Journal of Steroid Biochemistry and Molecular Biology
2009
89
15
Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved
Endocrine-Related Cancer
2013
88
16
Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia
Leukemia
2012
77
17
Aromatase inhibitors in breast cancer.
Endocrine-Related Cancer
2004
76
18
CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
PLoS ONE
2008
74
19
Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer
Radiotherapy and Oncology
2004
67
20
Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel
PLoS ONE
2011
65
21
An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples
Journal of Steroid Biochemistry and Molecular Biology
2008
62
22
Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors
BMC Cancer
2013
62
23
Patterns of genomic evolution in advanced melanoma
Nature Communications
2018
62
24
Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation
Clinical Cancer Research
2011
58
25
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
Breast Cancer Research
2012
58
26
P53 and its molecular basis to chemoresistance in breast cancer
Expert Opinion on Therapeutic Targets
2012
57
27
The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum
Annals of Oncology
2011
56
28
Breast cancer prognostication and prediction in the postgenomic era
Annals of Oncology
2007
55
29
Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia
Oncogene
2012
52
30
Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?
European Journal of Cancer
2009
51
31
Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis
Acta Oncológica
2007
47
32
MicroRNA-15b is induced with E2F-controlled genes in HPV-related cancer
British Journal of Cancer
2011
46
33
Lapatinib in early breast cancer—questions to be resolved
Lancet Oncology, The
2013
46
34
Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation
Journal of Investigative Dermatology
2015
46
35
Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers
Oncogene
2013
44
36
Chemoradiotherapy of Anal Carcinoma: Survival and Recurrence in an Unselected National Cohort
International Journal of Radiation Oncology Biology Physics
2012
43
37
SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer
European Journal of Cancer
2012
43
38
Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2–3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer
Annals of Oncology
2006
41
39
Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer
British Journal of Cancer
2012
41
40
The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy
Expert Opinion on Pharmacotherapy
2014
41
41
On the use of margins for geometrical uncertainties around the rectum in radiotherapy planning
Radiotherapy and Oncology
2004
40
42
Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors
Journal of Cancer Survivorship
2008
40
43
APOBEC3A/B deletion polymorphism and cancer risk
Carcinogenesis
2018
39
44
MDM2promoter SNP285 and SNP309; phylogeny and impact on cancer risk
Oncotarget
2011
39
45
Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study
Annals of Oncology
2010
38
46
RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer
Annals of Oncology
2011
38
47
Molecular basis for therapy resistance
Molecular Oncology
2010
37
48
Additive endocrine therapy for advanced breast cancer – back to the future
Acta Oncológica
2009
36
49
Twenty-five years with adjuvant chemotherapy for colon cancer – a continuous evolving concept
Acta Oncológica
2015
36
50
Testing the new ICRU 62 ‘Planning Organ at Risk Volume’ concept for the rectum
Radiotherapy and Oncology
2005
35
site/software ©
exaly
; All materials licenced under
CC by-SA
.